The combination of IL-17A and PD-1 blockade exhibited efficacy in CRC tumors, resulting in increased presence of cytotoxic T lymphocytes and decreased presence of myeloid-derived suppressor cells within the tumors [127]. The gene discussed is IL17A; the disease is colorectal carcinoma.